Technical Data
T8050-01N
TLR1, NT (Toll Like Receptor 1)
Description:
Description:
Toll-like receptors (TLRs) are evolutionarily conserved pattern-recognition molecules resembling the toll proteins that mediate antimicrobial responses in Drosophila. These proteins recognize different microbial products during infection and serve as an important link between the innate and adaptive immune responses (1-3). The TLRs act through adaptor molecules such as MyD88 and TIRAP to activate various kinases and transcription factors (4,5) so the organism can respond to potential infection. TLR1 is co-expressed with TLR2 on myeloid cells of the
innate immune systems in lymphoid tissue such as monocytes and dendritic cells (6) where they form heterodimers that can recognize triacylated lipoproteins (7).


Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1-2ug’ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.


TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceHumanRabbit
Concentration:
As reported
Immunogen:
Synthetic peptide TLR1 16aa near the amino terminus of human TLR1 (GenBank accession no. AAB94569).
Purity:
Purified by Ion Exchange chromatography.
Form
Supplied as a liquid in PBS, pH 7.2, 0.02% sodium azide.
Specificity:
Recognizes human TLR1. Species Crossreactivity: mouse.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Vogel SN, Fitzgerald KA, and Fenton MJ. TLRs: Mol. Interv. 2003; 3:466-77. 2. Takeda K, Kaisho T, and Akira S. Annu. Rev. Immunol. 2003; 21:335-76. 3. Janeway CA Jr. and Medzhitov R. Annu. Rev. Immunol. 2002; 20:197-216. 4. O’Neill LAJ, Fitzgerald FA, and Bowie AG. Trends in Imm. 2003; 24:286-9. 5. McGettrick AF and O’Neill LAJ. Mol Imm. 2004; 41:577-82. 6. Ochoa M-T, Legaspi AJ, Hatziris Z, et al. Immunol. 2003; 108:10-15. 7. Takeuchi O, Sato S, Horiuchi T, et al. J. Immunol. 2002; 169:10-4.